- Home
- » Tags
- » Pemafibrate
Top View
- ) (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, I
- Elucidation of Molecular Mechanism of a Selective PPAR Modulator
- 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
- Pharmaceutical Strategies for Reducing LDL-C and Risk of Cardiovascular Disease T
- Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
- PPAR Agonists and Metabolic Syndrome: an Established Role?
- Combination Therapy with Pemafibrate (K-877)
- PPAR-Mediated Toxicology and Applied Pharmacology
- The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARM) Paradigm: Conceptual Framework and Therapeutic
- Pparα Agonist Oral Therapy in Diabetic Retinopathy
- Exploration and Development of PPAR Modulators in Health and Disease : an Update of Clinical Evidence
- Report on the Deliberation Results June 13, 2017 Pharmaceutical
- Trends in Lipid-Modifying Agent Use in 83 Countries
- Present and Future of the Hypolipidemic Treatment, New Molecules in Sight
- Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study
- Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention
- New Trends in Dyslipidemia Treatment
- Lipid Modification to Reduce Cardiovascular Risk
- Current and Upcoming Pharmacotherapy for Non-Alcoholic Fatty Liver Disease Yaron Rotman,1 Arun J Sanyal2
- Efficacy and Safety of Pemafibrate Versus Fenofibrate In
- Novel Approaches to Lipid-Lowering Therapy
- Report on Investigation Results
- 1 Protocol Version: 1 Title: Comparative Effectiveness And
- 150-499 Mg/Dl) Michael S
- Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- WO 2018/193006 Al 25 October 2018 (25.10.2018) W !P O PCT